« Zurück
Startseite /
Irinotecan (hydrochloride trihydrate)

Irinotecan (hydrochloride trihydrate)

ArtNr	HY-16568-500mg
Hersteller	MedChem Express
CAS-Nr.	136572-09-3
Menge	500 mg
Quantity options	100 mg 10 mM/1 mL 200 mg 500 mg 50 mg
Kategorie	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Colorectal Cancer
Typ	Inhibitors
Specific against	other
Purity	99.89
Citations	[1]Morales C, et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb;56(3):219-26.\|[2]Pavillard V, et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr;49(4):329-35. Epub 2002 Jan 30.\|[3]Allegrini G, et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar;53(3):261-6. Epub 2003 Dec 5. J Mol Med (Berl). 2019 Aug;97(8):1183-1193.\|Acta Pharm Sin B. 2023 Dec 30.\|Adv Sci (Weinh). 2025 Jan 31:e2408845.\|Apoptosis. 2016 Feb;21(2):130-42. \|Biochem Pharmacol. 2023 Aug 25;115752.\|Biochim Biophys Acta Mol Basis Dis. 2024 Aug 16:167471.\|Biomaterials. 16 September 2022.\|Biomed Pharmacother. 2020 Aug;128:110262.\|Biomed Pharmacother. 2023 Apr 25;163:114751.\|bioRxiv. 2019 Dec.\|Cancer Lett. 2022 Nov 30;216028.\|Cell Biosci. 2023 Nov 25;13(1):215.\|Cell Death Dis. 2019 Nov 25;10(12):887. \|Cell Death Dis. 2024 Jun 15;15(6):417.\|Cell Death Dis. 2025 Jan 18;16(1):28.\|Cell Death Dis. 2025 Mar 12;16(1):170.\|Cell Discov. 2022 Sep 14;8(1):92.\|Cell Rep Med. 2023 Jan 10;100911.\|Cell Rep Med. 2024 Mar 19;5(3):101468.\|Cell Rep Methods. 2023 Oct 23;3(10):100599.\|Cell. 2022 Sep 1;185(18):3356-3374.e22.\|Clin Cancer Res. 2023 Sep 19.\|EBioMedicine. 2023 May 9;92:104594.\|Eur J Pharm Biopharm. 2022 Jan 5;S0939-6411(21)00272-1.\|Eur J Pharmacol. 2023 Apr 11;949:175718.\|Gastroenterology. 2021 Nov;161(5):1601-1614.e23.\|Gene. 2019 Mar 10;688:1-6. \|Genome Med. 2016 Oct 31;8(1):116.\|Heliyon. 2023 Apr 21.\|INT J PHARMACEUT. 2020 May.\|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.\|J Pharm Pharmacol. 2023 Mar 1;rgad007.\|Life Sci. 2019 Aug 15;231:116529. \|Lung Cancer. 2023 Mar 8;178:237-246.\|Mol Biol Cell. 2023 Mar 29;mbcE22110518.\|Mol Cancer Ther. 2021 Oct 28.\|Mol Cancer. 2024 Apr 4;23(1):70.\|Mol Cancer Res. 2020 Mar;18(3):414-423.\|Patent. US20210009719A1.\|Pharmacol Res. 2021 Jan;163:105232.\|PLoS Biol. 2022 Feb 24;20(2):e3001517.\|PLoS Pathog. 2020 Mar 24;16(3):e1008429.\|Redox Biol. 2024 May 23:73:103207.\|Signal Transduct Target Ther. 2021 May 28;6(1):188.\|Theranostics. 2019 May 31;9(13):3732-3753.\|Apoptosis. 2019 Apr;24(3-4):312-325.\|Cancers (Basel). 2023 Sep 6, 15(18), 4442.\|Front Immunol. 2018 Jan 5;8:1919.\|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.\|Oncogene. 2025 Mar 16.\|Ruperto Carola University Heidelberg. Natural Sciences and Mathematics. 18 March 2022.\|Sci Rep. 2024 Nov 26;14(1):29265.
Smiles	[H]Cl.O=C(N1CCC(N2CCCCC2)CC1)OC3=CC=C4N=C5C(CN6C(C(COC([C@@]7(CC)O)=O)=C7C=C65)=O)=C(CC)C4=C3.O.O.O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	(+)-Irinotecan (hydrochloride trihydrate),CPT-11 (hydrochloride trihydrate)
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Autophagy; Topoisomerase
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	677.18
Product Description	Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate) is a topoisomerase I inhibitor with antitumor activity[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 50 mg/mL (ultrasonic)\|Ethanol: 3.33 mg/mL (ultrasonic)\|H2O: 1.52 mg/mL (ultrasonic; warming)
Manufacturer - Pathway	Autophagy; Cell Cycle/DNA Damage
Isoform	Topo I
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-16568-500mg-safety-datasheet.pdf